Mission awarded $5.2m to advance potential Parkinson’s treatment
The progressive neurodegenerative condition affects around 153,000 people in the UK
Read More
Author: Jen Brogan
Study reveals mobile phone data can help map the spread of pathogens
Pneumococcus is the leading cause of pneumonia, meningitis and sepsis worldwide
Read More
NeuroSense Therapeutics shares positive results of lead candidate in ALS
The neurodegenerative disease currently affects more than 200,000 people worldwide
Read More
Study reveals genetic mutations associated with aggressive prostate cancer
Aggressive prostate cancer accounts for up to 15% of all prostate cancer diagnoses
Read More
Herantis Pharma granted €3.6m to assess treatment for Parkinson’s disease
In the UK, the progressive neurodegenerative condition affects around 153,000 people
Read More- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
